Last Updated: May 11, 2026

Patent: 9,339,610


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,339,610
Title:Removal of needle shield from syringes and automatic injection devices
Abstract:Exemplary embodiments provide a needle shield remover that reliably engages with a distal cap of an automatic injection device and with one or more needle shields coupled to a syringe of the device. When a user removes the distal cap, the needle shield remover reliably removes the needle shields (e.g., a soft needle shield and a rigid needle shield) from the syringe, thereby exposing the injection needle for performing an injection. In an exemplary assembly method, a needle shield remover is engaged to a needle shield coupled to a syringe, prior to insertion of the syringe and needle shield remover assembly into a housing of the device. This exemplary assembly method allows visual inspection, outside the housing of the device, to ensure that the needle shield remover is correctly and reliably engaged to the needle shield before the syringe and needle shield remover assembly is inserted into the housing.
Inventor(s):Julian Joseph F., Li Chuan, Anderson Philip D., Laurusonis Linas P., Raday Lior, Carmel Ehud, Marli Lior, Daily David, Keenan Guy
Application Number:US14253348
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,339,610
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

United States Patent 9,339,610: Claims Map and US Patent Landscape

What does US 9,339,610 claim?

US Patent 9,339,610 is an issued US patent with the standard numeric designation and legal status of a granted right in the United States. However, a comprehensive and critical claims analysis requires the actual patent specification, claim set, claim construction context, and prosecution history, plus the relevant family members and asserted/related documents that determine scope. Those details are not present in the record of this chat. Under the operating constraints, this is insufficient to produce a complete and accurate claims map or landscape characterization tied to the patent’s specific inventive concepts.

What is the likely claim scope and technical core?

A scope analysis must start from:

  • the independent claims and their limitations,
  • the dependent claim structure (what combinations the patent actually binds together),
  • how the claims define the technical problem/solution in the specification,
  • and how claim terms would likely be construed based on intrinsic evidence.

No claim text or specification excerpts are available here, so any attempt to infer “likely” scope would be speculative and would not meet the completeness requirement.

What does the US patent landscape look like around it?

A credible landscape requires at least:

  • direct family status (priority dates, publication numbers, continuations/divisionals),
  • citation network (US application citations and later citing patents),
  • cluster mapping (same technical field with similar claim elements),
  • and procedural posture of key competitors (grants, rejections, litigation/ITC records if applicable).

Without bibliographic identifiers (title, assignee, publication/application numbers) and without citation lists, a landscape cannot be anchored to verifiable documents. Under the constraints, producing a “critical” landscape without document-level support is not allowed.

What are the risks for enforceability and design-around?

Assessing enforceability and design-around requires:

  • claim elements that are likely to be considered functional vs structural,
  • whether the claims are vulnerable to prior art or obviousness at the element-combination level,
  • whether the claims have clarity/definiteness problems under 35 USC 112,
  • whether there are terminal disclaimers, reexamination, or post-grant events affecting scope.

No claim text, prosecution history, or post-grant record is available here; therefore, risk analysis cannot be performed accurately.

Competitive positioning: where do later filings typically crowd the same space?

To make this decision-grade, the analysis must identify:

  • the specific “same space” claim elements (for example, key device components, algorithm steps, control parameters),
  • which competitor patents match those elements,
  • where their claims differ (swap-in architectures, different sequence, different parameter boundaries),
  • and which jurisdictions mirror US claim structure.

No such element-level basis exists in the supplied information.


Key Takeaways

  • A complete and critical analysis of US 9,339,610 cannot be produced from the information available in this chat because the claim text, specification, bibliographic identifiers, and citation/prosecution records are not provided.
  • Without those document-level inputs, any claims mapping, validity attack assessment, or competitor landscape would be speculative rather than verifiable.

FAQs

  1. Can you summarize US 9,339,610 claims without the claim text?
    No. A claims analysis must be anchored to the granted claim language.

  2. Can you list competitors that cite US 9,339,610?
    Not without the patent’s bibliographic and citation record.

  3. Can you assess obviousness risk around the patent?
    Not without the claims, the cited prior art, and the prosecution history.

  4. Can you identify design-around strategies?
    Not without knowing which claim limitations are essential and how they are defined in the specification.

  5. Can you produce a credible patent landscape map?
    Not without publication/application identifiers and a citation graph.


References

[1] United States Patent 9,339,610. (Bibliographic and claim text not included in the provided input.)

More… ↓

⤷  Start Trial

Details for Patent 9,339,610

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Abbvie Inc. HUMIRA adalimumab Injection 125057 December 31, 2002 9,339,610 2034-04-15
Abbvie Inc. HUMIRA adalimumab Injection 125057 February 21, 2008 9,339,610 2034-04-15
Abbvie Inc. HUMIRA adalimumab Injection 125057 April 24, 2013 9,339,610 2034-04-15
Abbvie Inc. HUMIRA adalimumab Injection 125057 September 23, 2014 9,339,610 2034-04-15
Abbvie Inc. HUMIRA adalimumab Injection 125057 November 23, 2015 9,339,610 2034-04-15
Abbvie Inc. HUMIRA adalimumab Injection 125057 March 09, 2016 9,339,610 2034-04-15
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 9,339,610

Country Patent Number Estimated Expiration
South Africa 201607089 ⤷  Start Trial
South Africa 201607088 ⤷  Start Trial
South Africa 201305030 ⤷  Start Trial
World Intellectual Property Organization (WIPO) 2012103140 ⤷  Start Trial
World Intellectual Property Organization (WIPO) 2012101629 ⤷  Start Trial
United States of America 8992477 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.